Castle Biosciences, Inc. (NASDAQ:CSTL) Insider Derek J. Maetzold Sells 986 Shares of Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Derek J. Maetzold sold 986 shares of the firm’s stock in a transaction dated Tuesday, October 8th. The shares were sold at an average price of $30.27, for a total transaction of $29,846.22. Following the completion of the sale, the insider now owns 93,636 shares of the company’s stock, valued at $2,834,361.72. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

Castle Biosciences Stock Down 1.6 %

NASDAQ CSTL opened at $28.30 on Friday. The firm’s 50 day moving average is $28.46 and its 200-day moving average is $24.06. The company has a current ratio of 8.12, a quick ratio of 7.92 and a debt-to-equity ratio of 0.02. Castle Biosciences, Inc. has a 12-month low of $12.07 and a 12-month high of $32.53.

Castle Biosciences (NASDAQ:CSTL) last announced its quarterly earnings data on Monday, August 5th. The company reported $0.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.47. Castle Biosciences had a negative return on equity of 0.77% and a negative net margin of 1.08%. The company had revenue of $87.00 million for the quarter, compared to analysts’ expectations of $69.95 million. During the same quarter in the prior year, the business posted ($0.70) EPS. Equities research analysts predict that Castle Biosciences, Inc. will post -0.58 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have weighed in on CSTL shares. Robert W. Baird boosted their price objective on Castle Biosciences from $34.00 to $37.00 and gave the stock an “outperform” rating in a report on Tuesday, August 6th. Stephens reiterated an “overweight” rating and set a $37.00 target price on shares of Castle Biosciences in a report on Tuesday, August 6th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $32.80.

Hedge Funds Weigh In On Castle Biosciences

A number of institutional investors have recently bought and sold shares of CSTL. Vanguard Group Inc. lifted its holdings in Castle Biosciences by 2.2% during the 1st quarter. Vanguard Group Inc. now owns 1,494,176 shares of the company’s stock valued at $33,096,000 after purchasing an additional 32,695 shares during the last quarter. Acadian Asset Management LLC boosted its holdings in Castle Biosciences by 130.7% in the 1st quarter. Acadian Asset Management LLC now owns 210,824 shares of the company’s stock valued at $4,669,000 after purchasing an additional 119,443 shares during the period. Harbor Capital Advisors Inc. grew its position in Castle Biosciences by 249.3% during the second quarter. Harbor Capital Advisors Inc. now owns 138,707 shares of the company’s stock worth $3,020,000 after buying an additional 99,001 shares in the last quarter. Summit Global Investments acquired a new stake in shares of Castle Biosciences during the 2nd quarter worth $518,000. Finally, SG Americas Securities LLC bought a new position in Castle Biosciences in the 2nd quarter valued at about $588,000. Institutional investors and hedge funds own 92.60% of the company’s stock.

About Castle Biosciences

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.